Splash Beverage Group extends cannabinoid research into veterinary medicine with canine cancer and pain therapies

Splash Beverage Group aims to develop regulated cannabinoid therapies for dogs, focusing on cancer care and chronic pain, marking a shift into the stricter world of animal pharmaceuticals.

Splash Beverage Group is broadening its cannabinoid ambitions beyond human epilepsy and into veterinary medicine, with a programme aimed initially at canine cancer care and chronic pain.

According to the company, the move builds on its exclusive global rights to CannEpil, a pharmaceutical-grade cannabidiol and tetrahydrocannabinol formulation that has already been used in regulated patient-access settings in parts of Europe. Splash says its partner, Lupvindol Biosciences, will lead the scientific and regulatory work while the listed company funds development in stages and retains the resulting data and intellectual property.

The strategy is notable because it seeks to place a cannabinoid product in the far stricter world of animal drugs rather than the crowded pet-wellness market. The plan is to begin under the FDA’s Investigational New Animal Drug framework and explore conditional approval, a route that can bring therapies to market sooner for serious conditions in dogs if safety is established and there is a reasonable expectation of efficacy.

The programme is being steered by Hunter Land, whose past work included involvement in the development of Epidiolex, the first FDA-approved prescription CBD medicine for seizures in people. Splash argues that experience gives the project regulatory credibility.

For veterinarians, the commercial case is clear enough. Chronic pain and oncology remain major unmet needs, and a recent study in dogs suggested cannabidiol may reduce seizure frequency in drug-resistant epilepsy, though further data are still needed. Splash now wants to see whether a pharmaceutical cannabinoid can move from supplement-style promise to regulated veterinary therapy.

Image Source: Lupvindol